Postoperative Radiation Therapy in Pathologic T2-3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase 3, Randomized Controlled Study
W. Deng,J. Yang,Z. Xiao,X. Wang,Z. Zhou,H. Zhang,D. Chen,Q. Feng,J. Liang,J. Lv,T. Zhang,N. Bi,W. Wang,L. Deng,Z. Hui,L. Wang,J. He,S. Gao,Q. Xue,Y. Mao,K. Sun,X. Liu,D. Fang,J. Li,D. Wang,J. Mou,J. Zhao,Z. Li,W. Lei,Y. Wang,X. Chen
DOI: https://doi.org/10.1016/j.ijrobp.2017.06.474
2017-01-01
Abstract:Although NCCN guideline does not recommend adjuvant therapy after R0 resection for esophageal carcinoma, the reported recurrence rate of pathologic T2-3N0M0 esophageal patients varies between 41.6% and 51.8%, local regional recurrence rate reaches about 33.3%. Researches show postoperative radiotherapy could increase 5 year overall survival by 5.5%-8.0%. Our previous study has shown postoperative radiotherapy significantly increase 5-year OS (66.3% vs. 58.5%) and DFS (57.4% vs. 47.1%) compared with surgery alone. We launched this prospective, phase III, randomized controlled study primarily to explore the efficacy of postoperative radiotherapy in pathologic T2-3N0M0 thoracic esophageal squamous cell carcinoma patients. We randomly assigned R0 resection patients to surgery alone or to receive postoperative radiotherapy (IMRT) of 50.4 Gy in supraclavicular field and 56 Gy in mediastinal field (divided by upper rim of clavicular head) in 28 fractions over 5 weeks. Irradiation field was defined from cricothyroid membrane to 3 cm below carina (upper) or tumor bed (middle or lower), which involves 1, 2, 3, 4, 7, part 8 and 10L mediastinal lymph nodes. The primary endpoint was disease free survival. The secondary endpoint was local regional recurrence rate, overall survival, and toxicities. All analyses were done by intention-to-treat. The study is registered with ClinicalTrials.gov, number NCT01745107. From October 2012 to May 2017, 158 patients were enrolled in this study, 78 were assigned to surgery alone and 80 to postoperative radiotherapy. Baseline characteristics were well balanced between two groups, and 88.8% patients in postoperative radiotherapy group received radiotherapy. Median follow-up time is 35.6 months. To calculate survival time, we included 136 patients who were followed up more than 1 year except for that died within 1 year. Significant increases were seen in 1 and 2-year disease-free survival rate: 85.7%, 79.8% in postoperative radiotherapy group and 78.8%, 64.6% in surgery group (HR = 0.52; 95% CI = 0.28-0.97; P = 0.039). Whereas the 1, 2 year overall survival were not significantly different (95.7%, 91.1% in radiotherapy group vs. 95.5%, 90.7% in surgery group, P = 0.197). The overall recurrence rate was 29.4%. Local regional recurrence rate was significantly decreased in radiotherapy group (11.4% vs. 34.8% in surgery group, P = 0.001), while distant metastasis were not significant different between two groups (10.0% in radiotherapy group vs. 12.1% in surgery group, P = 0.693). Grade 3 toxicity rate associated with radiotherapy was 9.4%; no grade 4 or 5 toxicities were showed. Postoperative radiotherapy increased disease free survival and decreased local regional recurrence rate, in pathological T2-3N0M0 thoracic esophageal squamous cell carcinoma patients. No severe adverse events were showed. Further enrollment and follow-up are warranted to validate these findings in this ongoing trial.